医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

QIAGEN announces worldwide shipments of QIAstat-Dx test kits for SARS-CoV-2

2020年02月27日 AM06:00
このエントリーをはてなブックマークに追加


 

HILDEN, Germany & GERMANTOWN, Maryland

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has shipped its newly developed QIAstat-Dx Respiratory Panel 2019-nCoV test kit to four hospitals in China for evaluation. The new kit detects the novel coronavirus SARS-CoV-2 and adds rapid Sample to Insight syndromic testing to QIAGEN’s portfolio of molecular testing solutions in the public health emergency. QIAGEN is also in the process of shipping QIAstat-Dx testing kits to public health institutions in other regions, including Europe, South-East Asia, and the Middle East.

Since January QIAGEN has been providing instruments and consumables to support detection of the virus in China and other markets. Official protocols for SARS-CoV-2 detection include QIAGEN extraction kits, reagents and instruments for real-time polymerase chain reaction (RT-PCR) workflows. Customers also are deploying QIAsymphony modular instruments and NeuMoDx integrated PCR systems to automate higher-throughput processing of their laboratory-developed tests for SARS-CoV-2.

“Our dedicated task force has moved very fast to develop and make available the QIAstat-Dx respiratory panel with SARS-CoV-2 detection. We are partnering closely with authorities and customers around the world to bring rapid, accurate diagnosis to the fight against this deadly infectious disease,” said Thierry Bernard, Interim CEO of QIAGEN and Senior Vice President, Head of the Molecular Diagnostics Business Area. “As we have in past health crises such as SARS and the swine flu, QIAGEN is working hard to deliver better, faster testing solutions for hospitals and public health institutions to aid in the effort to monitor and bring the outbreak under control. Our employees’ extraordinary response embodies QIAGEN’s core mission to make improvements in life possible.”

Please find the full press release here

Further information can be also found here

View source version on businesswire.com: https://www.businesswire.com/news/home/20200226005803/en/

CONTACT

QIAGEN

Investor Relations

John Gilardi

+49 2103 29 11711

Phoebe Loh

+49 2103 29 11457

e-mail: ir@QIAGEN.com

Public Relations

Thomas Theuringer

+49 2103 29 11826

Robert Reitze

+49 2103 29 11676

e-mail: pr@QIAGEN.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Jichi Medical University and CureApp, Inc.: The First Phase 3 Clinical Trials of “Digital Therapeutics” for Hypertension Begin in Japan
  • EUSA Pharmaとイタリアのパパ・ジョヴァンニ23世病院がSISCO研究でシルツキシマブ治療を受けたCOVID-19患者の中間解析データを発表
  • EUSA Pharma和意大利Papa Giovanni XXIII医院提供Siltuximab治疗COVID-19患者的SISCO研究中期分析数据
  • Celltrion’s COVID-19 Antiviral Treatment Enters the Next Phase of Development
  • ‘Oracle Water’ Delivers Remarkable Ability of Effectively Sterilizing COVID-19